NasdaqGS:BIIBBiotechs
Biogen (BIIB) Stock Looks Near Fair Value After A 57% Run
Biogen stock has delivered a strong 57.5% return over the past year, yet the broader valuation checks suggest the shares now look closer to fairly priced than clearly cheap.
Over the last 12 months, Biogen has returned 57.5%, which puts more pressure on today’s buyers to justify the higher entry point with future execution.
Progress on newer therapies for Alzheimer’s disease and other conditions can support expectations for future cash flows. However, setbacks in clinical trials and legal...

